Clearing drug interferences in myeloma treatment using mass spectrometry

Mindy C. Kohlhagen, John R. Mills, Maria A.V. Willrich, Surendra Dasari, Angela Dispenzieri, David L. Murray

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To explore the possibility of using a combination of a rapid MALDI-TOF-MS method (Mass-Fix) in conjunction with higher resolution LC-ESI-QTOF-MS (miRAMM) measurements to discriminate the IgG kappa M-protein from daratumumab, elotuzumab and isatuximab in myeloma patients. Design & Methods: 86 patients with an IgG kappa M-protein were spiked with therapeutic levels of the drugs and examined by Mass-Fix and miRAMM to establish the percent of cases that could be resolved by each method. The method was then applied to 21 samples from patients receiving one of the drugs. Results: Mass-Fix was capable of resolving the t-mAb from M-protein for 87 percent of the spiked samples. For the cases unresolved by Mass-Fix, miRAMM was capable of resolving the remaining drug interferences. The 21 IgG kappa myeloma patients that were receiving the drugs were all resolved by Mass-Fix. Conclusion: This proposed algorithm allows use of a clinical available assay (Mass-Fix) while maximizing the number of cases that can accurately resolve the t-mAb from the M-protein.

Original languageEnglish (US)
JournalClinical Biochemistry
DOIs
StateAccepted/In press - 2021

Keywords

  • Immunofixation electrophoresis
  • MALDI-TOF MS
  • Multiple myeloma
  • Plasma cell disease
  • Serum protein electrophoresis
  • Therapeutic monoclonal antibodies

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Clearing drug interferences in myeloma treatment using mass spectrometry'. Together they form a unique fingerprint.

Cite this